摘要
目的探讨肺癌患者痰液脱落细胞中信号传导通路基因(rasassociation domainfamily 1A,RASSF1A)和腺瘤样息肉病基因(adenomatous polyposis coli,APC)、T-钙黏蛋白13(cadherin-13,CDH13)和p16基因甲基化的发生状态,及其联合检测在肺癌早期筛查及诊断中的作用和意义。方法选取2015年1月至2017年12月本院收治的50例肺癌患者,50例肺部良性病变患者和50例正常人痰液标本,采用甲基化特异性PCR法(methylation specific PCR,MSP)检测患者痰液脱落细胞中APC、p16、CDH13和RASSF1A基因启动子区域甲基化发生情况。结果肺癌患者痰标本中APC、p16、CDH13和RASSF1A基因启动子区甲基化发生率分别为38.00%(19/50)、54.00%(27/50)、34.00%(17/50)和26.00%(13/50)。患者痰标本基因APC、p16、CDH13和RASSF1A基因启动子区甲基化率与患者年龄、性别、组织学分型和临床分期无关,差异不具有统计学意义(P<0.05)。患者痰标本基因APC、p16、CDH13和RASSF1A基因启动子区甲基化率与患者吸烟指数明显相关,差异具有统计学意义(P>0.05)。结论肺癌患者痰液脱落细胞中APC、p16、CDH13和RASSF1A基因甲基化的联合检测可以提示有效临床肺癌的发生情况。
Objective To investigate the expression of RASSF1A and APC, CDH13,）And p16 gene methylation status, and its combined detection of early screening and diagnosis of lung cancer in the role and significance. Methods Fifty patients with lung cancer, 50 patients with benign lung disease and 50 normal sputum from 2015/1 - 2017/12 were enrolled in this study. Methylation specific PCR （MSP） The methylation of APC ,p16 ,CDH13 and RASSF1A gene promoter regions in sputum exfoliated ceils of patients. Results The methylation rates of APC, p16, CDH13 and RASSF1A gene promoter in sputum from patients with lung cancer were 38.00% （19/50） ,54.00% （27/50） ,34.00% （ 17/50 and 26.00 % （13/50）. The methylation rates of APC, p16, CDH13 and RASSF1A gene promoter in sputum specimens had no correlation with patient age,sex,histological type and clinical stage （ P 〈 0.05 ）. The methylation rates of APC, p16, CDH13 and RASSF1A gene promoter in patients with sputum specimens were significantly correlated with smoking index of patients （ P 〉 0.05 ）. Conclusion The combined detection of methylation of APC, p16, CDH13, and RASSF1A genes in sputum exfoliated cells in lung cancer patients may indicate the occurrence of effective clinical lung cancer.
作者
钟云华
李燕
陆炳团
ZHONG Yun-hua;LI Yan;LU Bing-tuan(The Department of Geriatrics,the First People＇s Hospital of Yunnan,Affiliated Hospital of Kunming University of Science and Technology,Kunming 650032,China)
出处
《标记免疫分析与临床》
CAS
2018年第8期1214-1217,1222,共5页
Labeled Immunoassays and Clinical Medicine
基金
云南省应用基础研究(昆医联合)专项[编号:2017FE467(-116)]
云南省卫生科技计划项目(编号:2016NS204)
